Tyra Biosciences (TYRA) Total Current Liabilities (2020 - 2026)
Tyra Biosciences' (TYRA) quarterly Total Current Liabilities came in at $19.3 million in Q1 2026, up 35.17% YoY from $14.2 million in Q1 2025, and up 6.42% on a QoQ basis from $18.1 million in Q4 2025.
Tyra Biosciences (TYRA) Total Current Liabilities (2020 - 2026) Analysis & Trends
Tyra Biosciences (TYRA) has 7 years of Total Current Liabilities data on file, last reported at $19.3 million in Q1 2026.
- Quarterly Total Current Liabilities rose 35.17% year-over-year to $19.3 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $19.3 million (up 35.17% YoY) and the FY2025 annual result came in at $18.1 million, up 23.98% from the prior year.
- Total Current Liabilities improved to $19.3 million in Q1 2026, from $18.1 million in the prior quarter.
- In the past five years, Total Current Liabilities ranged from a high of $19.3 million in Q1 2026 to a low of $3.7 million in Q1 2023.
- A 5-year average of $10.8 million and a median of $10.4 million in 2024 frame the typical range for Total Current Liabilities.
- The widest YoY moves for Total Current Liabilities: up 168.95% in 2023, down 24.87% in 2023.
- Tracing TYRA's Total Current Liabilities over 5 years: stood at $5.7 million in 2022, then soared by 168.95% to $15.3 million in 2023, then slipped by 4.82% to $14.6 million in 2024, then rose by 23.98% to $18.1 million in 2025, then rose by 6.42% to $19.3 million in 2026.
- The last three Total Current Liabilities figures came in at $19.3 million (Q1 2026), $18.1 million (Q4 2025), and $15.9 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 3.94 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 5.53 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.58 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 354.06 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 2.12 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 4.22 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 630.93 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 1.51 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 438.74 Mn |
| 10 | Tyra Biosciences | 1.51 Bn | 1.51 Bn | - | 24.62 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 24.62 Mn |
| Mar 31, 2026 | 19.26 Mn |
| Dec 31, 2025 | 18.09 Mn |
| Sep 30, 2025 | 15.88 Mn |
| Jun 30, 2025 | 13.77 Mn |
| Mar 31, 2025 | 14.25 Mn |
| Dec 31, 2024 | 14.59 Mn |
| Sep 30, 2024 | 12.37 Mn |
| Jun 30, 2024 | 10.38 Mn |
| Mar 31, 2024 | 8.72 Mn |
| Dec 31, 2023 | 15.33 Mn |
| Sep 30, 2023 | 10.15 Mn |
| Jun 30, 2023 | 5.41 Mn |
| Mar 31, 2023 | 3.68 Mn |
| Dec 31, 2022 | 5.70 Mn |
| Sep 30, 2022 | 5.49 Mn |
| Jun 30, 2022 | 5.46 Mn |
| Mar 31, 2022 | 4.90 Mn |
| Dec 31, 2021 | 3.62 Mn |
| Sep 30, 2021 | 4.77 Mn |